05267.
Josamycin

| Explanatory Notes [16846-24-5] Leucomycin V 3-acetate 4B-(3-methylbutanoate); leucomycin A3; EN-141; Iosalide (Schering); Jomybel (Sarva); Josamina (Novag). C42H69NO15; mw 827.99. C 60.92%, H 8.40%, N 1.69%, O 28.98%. Macrolide antibiotic produced by Streptomyces narbonensis var. josamyceticus nov. var. Isoln and characterization: T. Osono et al., J. Antibiot. 20A, 174 (1967). Manuf process: H. Umezawa,T. Osono, JP 66 21759 (1966 to Microbiochemical Res. Found.), C.A. 66, 54258w (1967). Prepn: Y. Oka et al., JP Kokai 76 41497 (1976 to Yamanouchi), C.A. 85, 121788b (1976). Identification with leucomycin A3: S. Omura et al., J. Antibiot. 23, 511 (1970). Structure: eidem, ibid. 27, 366 (1974). Absolute configuration: A. Ducruix et al., Chem. Commun. 1976, 947. Stereospecific total synthesis: K. Tatsuta et al., Tetrahedron Lett. 1980, 2837. Retrosynthetic studies: K. C. Nicolaou et al., J. Am. Chem. Soc. 103, 1222 (1981). A 17-membered aglycone was proposed at one time, see T. Osono, H. Umezawa in Drug Action and Drug Resistance in Bacteria 1, S. Mitsuhashi, Ed. (University Park Press, Baltimore, 1971) pp 41-120; T. Osono et al., J. Antibiot. 27, 366 (1974). Pharmacology: K. Kuriaki et al., Jpn. J. Antibiot. 22, 232 (1969). Review: T. Osono, H. Umezawa, loc. cit. |
The Merck Index, 14th Edition ver. 14.4.
Copyright © 2006, 2009 by Merck & Co., Inc., Whitehouse Station, New Jersey, USA. All Rights Reserved.
Reproduction of any portion of The Merck Index without the written consent of Merck & Co., Inc. is prohibited.